Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 11/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10727790 | 0.95 | CYP2C19 (0.37) | DGAT1CYP2C19CYP1A2USP2ALDH1A1 | |
| SCHEMBL10727800 | 0.95 | CYP2C19 (0.37) | DGAT1CYP2C19CYP1A2USP2ALDH1A1 | |
| SCHEMBL1617974 | 0.95 | CYP2C19 (0.37) | DGAT1CYP2C19CYP1A2USP2ALDH1A1 | |
| SCHEMBL10412652 | 0.93 | CYP2C19 (0.40) | DGAT1CYP2C19CYP1A2USP2ALDH1A1 | |
| SCHEMBL8624485 | 0.82 | GRIN2D (0.36) | CYP2C19LMNATSHR | |
| SCHEMBL8663002 | 0.82 | SIRT2 (0.41) | ALDH1A1TSHR | |
| SCHEMBL2765891 | 0.81 | DGAT1 (0.37) | DGAT1CYP2C19CYP1A2USP2ALDH1A1 | |
| SCHEMBL10729067 | 0.77 | MME (0.37) | LMNATSHR | |
| SCHEMBL10729071 | 0.77 | MME (0.37) | LMNATSHR | |
| SCHEMBL10798606 | 0.77 | GPR84 (0.39) | ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167281-A1 | 1,2,4- Trioxepanes as precursors for lactones | AKZO NOBEL N.V. (NL) | 2006-07-27 | — | — | US | claimed |
| US-20060167281-A1 | 1,2,4- Trioxepanes as precursors for lactones | AKZO NOBEL N.V. (NL) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167281-A1 | 1,2,4- Trioxepanes as precursors for lactones | CYP4X1, LSS, RIOX2 | DGAT1 2719/4885CYP2C19 1173/4885CYP1A2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.